ASCO 2019 | ENZAMET: Enzalutamide for metastatic prostate cancer

Ian Davis, MB BS, PhD, FRACP, FAChPM, of the Monash University Eastern Health Clinical School, Melbourne, Australia, discusses the ENZAMET (NCT02446405) trial which investigated the effectiveness of enzalutamide, versus a conventional non-steroidal anti-androgen (NSAA), when combined with a luteinizing hormone-releasing hormone analog (LHRHA) or surgical castration, as first-line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer. Prof. Davis goes on to discuss the good work the ANZUP Cancer Trial Group are currently doing for people affected by genitourinary cancers at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.